Dupilumab, a fully human monoclonal antibody that simultaneously blocks IL-4 and IL-13 signals by targeting IL-4Rα, is anticipated to be a valuable addition to the therapeutic intervention for PV (176), as demonstrated in several case reports in recent years (177–179). This evidence concerns the gene IL4 and acquired polycythemia vera.